Itamar Medical and Roche Sign Agreement For EndoPAT™ Devices in Pre-Clinical Drug Development

Non Invasive Endothelial Dysfunction technology of choice for innovative testing for cardiovascular drug development.

CAESAREA, Israel--(BUSINESS WIRE)-- Itamar Medical (TASE:ITMR), the leader in non-invasive vascular health diagnostics, announced today that an agreement has been signed with Roche (SIX:RO, ROG; OTCQX:RHHBY) by which Itamar will develop an EndoPAT device designated for use with animal models, enabling pre-clinical studies examining the efficacy of various compounds in the early stage of drug development essential for later stage development in humans. Itamar’s EndoPAT device is a non-invasive technology designed to diagnose and monitor endothelial dysfunction, which constitutes an early stage of cardiovascular diseases in humans. “Following on from our work with Roche in clinical studies, we are pleased to further our collaboration that will reinforce our strategy of EndoPAT playing a major role in developing personalized medicine and companion diagnostics,” said Dr. Dov Rubin, Itamar Medical's President and CEO.

“EndoPAT offers the only non-invasive, FDA-cleared technology for detecting endothelial dysfunction that is easily applied and totally operator independent in humans,” said Dr. Koby Sheffy, Itamar Medical’s CTO and Senior Vice President. “This advanced development positions the EndoPAT to be the technology of choice to assess endothelial dysfunction in cardiovascular drugs development from the early animal model through the different clinical phase trials in humans.”

About Itamar Medical

Itamar Medical Ltd. is a publicly-traded medical technology company (TASE: ITMR) utilizing PAT™ (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive “window” to both the cardiovascular and autonomic nervous systems.

Itamar Medical is the developer of EndoPAT, which diagnoses endothelial dysfunction – an important state in the development and progress of atherosclerosis affecting both early and late stages of the disease. EndoPAT has now been deployed by over 10 pharmaceutical companies, many of which are among the Fortune 100, in nearly 20 large-scale drug development studies, and has been proven to shorten the time and reduce the cost of drug development.

For more information, visit

For further public relations information: Daphna Triwaks, Head of Public Relations, +972-3-647-5777; [email protected]


for Itamar Medical
Daphna Triwaks, +972-3-647-5777
Head of Public Relations
[email protected]

KEYWORDS:   Europe  Middle East  Switzerland  Israel

INDUSTRY KEYWORDS:   Health  Cardiology  Clinical Trials  Medical Devices  Pharmaceutical